Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

Hepatology

Volumn 29, Issue 4, 1999, Pages 1124-1130

  Ikeda, Kenji ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Chayama, Kazuaki ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Tsubota, Akihito ^a   Kobayashi, Mizuho ^a   Nakamura, Ikuo ^a   Murashima, Naoya ^a   Kumada, Hiromitsu ^a   Kawanishi, Masahiro ^b  

^a TORANOMON HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0032898360     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290439     Document Type: Article

References (24)

1. Bruix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R, Barrera JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006.
2. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008.
3. Hasan F, Jeffers LJ, Medina MD, Reddy KR, Parker T, Schiff ER, Houghton M, et al. Hepatitis C-associated hepatocellular carcinoma. HEPATOLOGY 1990;12:589-591.
4. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990;335: 873-874.
5. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis - a prospective observation of 795 cases with viral and alcoholic cirrhosis. HEPATOLOGY 1993;18:47-53.
6. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
7. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis - a prospective observation of 2215 patients. J Hepatol 1998;28:930-938.
8. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
9. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
10. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
11. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. HEPATOLOGY 1991;13:1040-1043.
12. Yoshioka K, Kakumu S, Hayashi H, Shinagawa T, Wakita T, Ishikawa T, Itoh Y, et al. Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: relation to disease progression and effect of interferon alpha. Am J Gastroenterol 1991;86:1495-1499.
13. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
14. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877-883.
15. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
16. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrica 1982;69:553-566.
17. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:248-275.
19. SAS Institute Inc. SAS/STAT User's Guide, Release 6.11 Edition. Cary, NC, 1996.
20. Gaeta GB, Rapicetta M, Sardaro C, Chionne P, Costantino A, Giusti G. High prevalence of co-occurrence of anti-HCV and anti-HBc antibodies in chronic hepatitis patients from southern Italy. Ital J Gastroenterol 1990;22:350-351.
21. Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles county, California. HEPATOLOGY 1997;25:226-228.
22. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54:249-255.
23. Moreno MG, Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol 1995;50:515-520.
24. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, Tanabe H, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-694.